関連する実験動画

Updated: Jul 1, 2026

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse
08:08

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

Published on: November 10, 2008

アルツハイマー病の臨床進行を予測するための統合されたCSF-血清バイオマーカーモデル

Xichun Wang1, Ye Tang2, Qiwen Zhang3

  • 1Department of Neurology, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen, China.

Frontiers in aging neuroscience
|February 12, 2026
PubMed
まとめ

脳脊髄液 (CSF) pTau181を血清アルブミン対グローブリン (A/G) 比,血小板対リンパ球比 (PLR) と組み合わせると,アルツハイマー病 (AD) の進行を正確に予測できます. この統合されたバイオマーカーのアプローチは,ADリスクの階層化の診断の精度を高めます.

キーワード:
アルツハイマー病 (Alzheimer's disease) とは,アルツハイマー病 (Alzheimer's disease) とは,アルツハイマー病 (Alzheimer's disease) とは,アルツハイマー病 (Alzheimer's disease) とは,アルブミンとグローブリン比率はノモグラム・ノモグラムpTau181 1pTau181 1pTau181 1pTau181 1pTau181 1pTau181 1pTau181 1pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 3pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181 2pTau181血小板とリンパ球の比率は

さらに関連する動画

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data09:47

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

Published on: December 15, 2023

関連する概念動画

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...